C3 and paroxysmal nocturnal hemoglobinuria: Recently, a specific C3 inhibitor, pegcetacoplan (Empaveli, Apellis Pharmaceuticals, Waltham, MA), was approved to treat paroxysmal nocturnal hemoglobinuria (34), and further studies should evaluate if C3 inhibitors can be used to dampen thromboinflammation triggered by air embolism.